新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内 ESG 生态体系的加速完善，政策监管持续收紧、资本市场对 ESG 表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的 重要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建 18套行业ESG评价模型，纳入150余项 ESG 指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国 ESG 实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 上海医药在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，上海医药成功入选本 次 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of Pyridostigmine oral solution, which is used to treat myasthenia gravis [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Bromides of Pyridostigmine oral solution [1] - The drug was first launched in the United States in 1965, indicating a long history of use in the treatment of myasthenia gravis [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the oral solution, which is used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The oral solution of Bromides has been granted a drug registration certificate (Certificate No: 2025S04074) by the National Medical Products Administration [1] - The product was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - Shanghai Pharmaceuticals submitted the registration application for this product in April 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 2.3174 million in research and development for this product as of the date of the announcement [1] - There are currently no other companies in China that have this product listed for sale [1] Group 3: Market Potential - According to the IQVIA database, the procurement amount for Bromides tablets in hospitals in mainland China is RMB 60.29 million for the year 2024 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of bromhexine oral solution, indicating a significant advancement in its product portfolio [1] Group 1 - Shanghai Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd., has obtained a drug registration certificate for bromhexine oral solution [1] - The drug registration certificate number is 2025S04074, confirming the approval for production [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於溴吡斯的明口服溶液獲得批准生產的公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 10 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 证券代码：601607 证券简称：上 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for its oral solution of Pyridostigmine Bromide, which is approved for production [1] Group 1 - The oral solution of Pyridostigmine Bromide is used for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1965 [1] - Shanghai Shiyou submitted the registration application for this drug to the National Medical Products Administration in April 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 2.3174 million in research and development for this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

Group 1 - The core point of the article is that Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the Ming oral solution, which is used to treat myasthenia gravis [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - As of the announcement date, the company has invested approximately 2.3174 million yuan in the research and development of this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

关于溴吡斯的明口服溶液获得批准生产的公告 上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 编号：临 2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海上药中西 制药有限公司（以下简称"上药中西"）的溴吡斯的明口服溶液（以下简称"该 药品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注 册证书》（证书编号：2025S04074），该药品获得批准生产。 一、该药品基本情况 药品名称：溴吡斯的明口服溶液 剂型：口服溶液剂 规格：473ml：5.676g 注册分类：化学药品 3 类 药品批准文号：国药准字 H20256499 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 截至本公告日，中国境内该药品暂无其他企业上市。 IQVIA 数据库显示，2024 年中国大陆医院采购溴吡斯的明片剂金额为人民 币 6,029 万元。 1 三、对上市公司影响及 ...

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Bromides of the Ming oral solution, which is approved for production and is used to treat myasthenia gravis [1] Group 1 - The drug Bromides of the Ming oral solution was originally developed by BAUSCH and was first launched in the United States in 1965 [1]